Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Verastem, Inc. (NASDAQ:VSTM) Director Robert E. Gagnon sold 284 shares of common stock on June 16, 2025, at a price of $5.65, for a total transaction value of $1604. The transaction comes as VSTM shares have delivered an impressive 60% return over the past year, despite the company’s current Weak financial health score according to InvestingPro data.
The sale was executed to satisfy statutory withholding requirements related to the vesting of restricted stock units. Following the transaction, Gagnon directly owns 42,242 shares of Verastem, Inc. While the company holds more cash than debt on its balance sheet, analysts have set price targets ranging from $13 to $20, suggesting potential upside. For deeper insights into insider trading patterns and comprehensive financial analysis, explore the detailed Pro Research Report available on InvestingPro.
In other recent news, Verastem Oncology has reported promising results from its Phase 1/2 trials. The trials focused on the drug GFH375, also known as VS-7375, which demonstrated an overall response rate of 52% in pancreatic ductal adenocarcinoma patients and 42% in non-small cell lung cancer patients. Additionally, Verastem’s RAMP 205 trial showed an 83% overall response rate in treating metastatic pancreatic ductal adenocarcinoma. The company is planning a Phase 3 study for this treatment in 2026 following FDA approval for its combination therapy of avutometinib and defactinib for KRAS-mutated ovarian cancer.
Analysts have shown confidence in Verastem’s research initiatives, with Cantor Fitzgerald reaffirming an Overweight rating. Jefferies has raised the company’s price target to $19, highlighting the early FDA approval as a significant milestone. Mizuho (NYSE:MFG) maintains an Outperform rating with an $8 price target, noting the company’s recent $75 million financing and potential for upcoming data catalysts. These developments underscore Verastem’s strategic focus on advancing cancer treatments and its growing presence in the oncology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.